tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Wilson CH et al. | Prospective randomised trial of the use of Daclizumab in renal transplantation using kidneys from non heart beating donors. | 2004 | Ann. Transplant. | pmid:15478912 |
| Muraki Y et al. | Impact of CYP3A5 genotype of recipients as well as donors on the tacrolimus pharmacokinetics and infectious complications after living-donor liver transplantation for Japanese adult recipients. | 2011 Oct-Dec | Ann. Transplant. | pmid:22210422 |
| Boratyńska M et al. | Conversion from cyclosporine-based immunosuppression to tacrolimus/mycophenolate mofetil in patients with refractory and ongoing acute renal allograft rejection. | 2006 | Ann. Transplant. | pmid:17494290 |
| Foroncewicz B et al. | A comparison between two tacrolimus-based immunosuppression regimens in renal transplant recipients: 7-year follow-up. | 2013 | Ann. Transplant. | pmid:23896824 |
| Grochowiecki T et al. | A retrospective study of steroid elimination in simultaneous pancreas and preemptive kidney transplant (Sppre-Ktx) recipients. | 2006 | Ann. Transplant. | pmid:17494291 |
| Arreola-Guerra JM et al. | Tacrolimus Trough Levels as a Risk Factor for Acute Rejection in Renal Transplant Patients. | 2016 | Ann. Transplant. | pmid:26879833 |
| Rhu J et al. | Clinical Implication of Mycophenolic Acid Trough Concentration Monitoring in Kidney Transplant Patients on a Tacrolimus Triple Maintenance Regimen: A Single-Center Experience. | 2017 | Ann. Transplant. | pmid:29180612 |
| Mocchegiani F et al. | Tacrolimus and Everolimus de novo versus minimization of standard dosage of Tacrolimus provides a similar renal function at one year after liver transplantation: a case-control matched-pairs analysis. | 2014 | Ann. Transplant. | pmid:25347718 |
| Rehman S et al. | Effect of different tacrolimus levels on early outcomes after kidney transplantation. | 2014 | Ann. Transplant. | pmid:24509826 |
| Legris T et al. | Humoral immunity after kidney transplantation: impact of two randomized immunosuppressive protocols. | 2013 | Ann. Transplant. | pmid:24231646 |
| Bäckman L and Persson CA | An observational study evaluating tacrolimus dose, exposure, and medication adherence after conversion from twice- to once-daily tacrolimus in liver and kidney transplant recipients. | 2014 | Ann. Transplant. | pmid:24637379 |
| Girman P et al. | The effect of bone marrow transplantation on survival of allogeneic pancreatic islets with short-term tacrolimus conditioning in rats. | 2001 | Ann. Transplant. | pmid:11803619 |
| Steinebrunner N et al. | Pharmacodynamic monitoring of nuclear factor of activated T cell-regulated gene expression in liver allograft recipients on immunosuppressive therapy with calcineurin inhibitors in the course of time and correlation with acute rejection episodes--a prospective study. | 2014 | Ann. Transplant. | pmid:24457606 |
| Wu YJ et al. | Safe One-to-One Dosage Conversion From Twice-Daily to Once-Daily Tacrolimus in Long-Term Stable Recipients After Liver Transplantation. | 2016 | Ann. Transplant. | pmid:26782179 |
| Gijsen VM et al. | Tacrolimus-induced nephrotoxicity and genetic variability: a review. | 2012 Apr-Jun | Ann. Transplant. | pmid:22743729 |
| Czubkowski P et al. | Cardiovascular risk factors after conversion from cyclosporine to tacrolimus in children after liver transplantation. | 2014 | Ann. Transplant. | pmid:25409773 |
| Gerlach UA et al. | Aspergillus spondylodiscitis after multivisceral transplantation. | 2009 Oct-Dec | Ann. Transplant. | pmid:20009156 |
| Aguiar D et al. | Real-World Multicenter Experience of Immunosuppression Minimization Among 661 Liver Transplant Recipients. | 2017 | Ann. Transplant. | pmid:28461684 |
| Malinowski M et al. | Effect of tacrolimus dosing on glucose metabolism in an experimental rat model. | 2010 Jul-Sep | Ann. Transplant. | pmid:20877268 |
| Roan JN et al. | Dose-normalization for exposure to mycophenolic acid and the early clinical outcome in patients taking tacrolimus after heart transplantation. | 2013 | Ann. Transplant. | pmid:23792500 |
| Tanaka T et al. | Evaluation of immune function under conversion from Prograf to Advagraf in living donor liver transplantation. | 2013 | Ann. Transplant. | pmid:23792533 |
| Ueda K et al. | Early corticosteroid withdrawal in the real world: a long-term analysis of kidney transplant recipients from the Mycophenolic Acid Observational Renal Transplant Registry. | 2014 | Ann. Transplant. | pmid:24535029 |
| El-Agroudy AE et al. | Long-term graft outcome in patients with chronic allograft dysfunction after immunosuppression modifications. | 2008 | Ann. Transplant. | pmid:19034223 |
| Augusto JF et al. | Long-term maintenance immunosuppressive regimen with tacrolimus monotherapy. | 2013 | Ann. Transplant. | pmid:23872516 |
| Miyata Y et al. | Pharmacokinetics of a Once-Daily Dose of Tacrolimus Early After Liver Transplantation: With Special Reference to CYP3A5 and ABCB1 Single Nucleotide Polymorphisms. | 2016 | Ann. Transplant. | pmid:27503662 |
| Herden U et al. | Early Initiation of Everolimus After Liver Transplantation: A Single-Center Experience. | 2016 | Ann. Transplant. | pmid:26842532 |
| Zegarska J et al. | Mycophenolic Acid Metabolites Acyl-Glucuronide and Glucoside Affect the Occurrence of Infectious Complications and Bone Marrow Dysfunction in Liver Transplant Recipients. | 2015 | Ann. Transplant. | pmid:26313036 |
| Figurski MJ et al. | Pharmacokinetic monitoring of mycophenolic acid in heart transplant patients: correlation the side-effects and rejections with pharmacokinetic parameters. | 2012 Jan-Mar | Ann. Transplant. | pmid:22466911 |
| Acott P and Babel N | BK virus replication following kidney transplant: does the choice of immunosuppressive regimen influence outcomes? | 2012 Jan-Mar | Ann. Transplant. | pmid:22466913 |
| Bułanowski M et al. | Influence of conversion from cyclosporine A to tacrolimus on insulin sensitivity assessed by euglicaemic hyperinsulinemic clamp technique in patients after kidney transplantation. | 2012 Jul-Sep | Ann. Transplant. | pmid:23018257 |
| Schmid S et al. | Volatility of serum creatinine relative to tacrolimus levels predicts kidney transplant rejection. | 2014 | Ann. Transplant. | pmid:25123847 |
| Remiszewski P et al. | Orthotopic liver transplantation for acute liver failure resulting from "acute fatty liver of pregnancy". | 2003 | Ann. Transplant. | pmid:15114933 |
| Ogura Y et al. | Early Conversion From Twice-Daily Tacrolimus to Prolonged-Release Tacrolimus in Liver Transplantation: A Single-Center Experience. | 2016 | Ann. Transplant. | pmid:27432248 |
| Dedinská I et al. | Waist circumference as an independent risk factor for NODAT. | 2015 | Ann. Transplant. | pmid:25791039 |
| Zahn A et al. | Mycophenolate mofetil combination therapy improves survival after liver transplantation. A single-center retrospective analysis. | 2013 | Ann. Transplant. | pmid:24088725 |
| Garaix F et al. | Tacrolimus Granules for Oral Suspension as Post-Transplant Immunosuppression in Routine Medical Practice in France: The OPTIMOD Study. | 2018 | Ann. Transplant. | pmid:30093607 |
| Matia I et al. | Immunosuppressive protocol with delayed use of low-dose tacrolimus after aortic transplantation suppresses donor-specific anti-MHC class I and class II antibody production in rats. | 2014 | Ann. Transplant. | pmid:24815872 |
| Gardiner KM et al. | Multinational Evaluation of Mycophenolic Acid, Tacrolimus, Cyclosporin, Sirolimus, and Everolimus Utilization. | 2016 | Ann. Transplant. | pmid:26729299 |
| Rostaing L et al. | The pharmacokinetics of everolimus in de novo kidney transplant patients receiving tacrolimus: an analysis from the randomized ASSET study. | 2014 | Ann. Transplant. | pmid:25017487 |
| Jannot M et al. | Early conversion from twice-daily tacrolimus to once-daily extended formulation in renal transplant patients before hospital discharge. | 2014 | Ann. Transplant. | pmid:24999809 |
| Urbanowicz T et al. | Comparison of conventional tacrolimus versus prolong release formula as initial therapy in heart transplantation. | 2014 | Ann. Transplant. | pmid:24949728 |
| Tang JT et al. | A Low Fixed Tacrolimus Starting Dose Is Effective and Safe in Chinese Renal Transplantation Recipients. | 2018 | Ann. Transplant. | pmid:29735966 |
| Fuchs U et al. | Incidence of malignant neoplasia after heart transplantation--a comparison between cyclosporine a and tacrolimus. | 2014 | Ann. Transplant. | pmid:24953848 |
| Abdel Halim M et al. | Toxic tacrolimus blood levels with rifampin administration in a renal transplant recipient. | 2010 Jan-Mar | Ann. Transplant. | pmid:20305320 |
| Foroncewicz B et al. | Cyclosporine is superior to tacrolimus in liver transplant recipients with recurrent psoriasis. | 2014 | Ann. Transplant. | pmid:25163829 |
| Bösmüller C et al. | Tacrolimus monotherapy following alemtuzumab induction in combined kidney-pancreas transplantation: results of a prospective randomized trial. | 2012 | Ann. Transplant. | pmid:23274323 |
| Olczak-Kowalczyk D et al. | The status of dental and jaw bones in children and adolescents after kidney and liver transplantation. | 2012 | Ann. Transplant. | pmid:23274327 |
| Schnitzbauer AA et al. | Delayed bottom-up and amended simple method of dosing with once-daily tacrolimus application to achieve stable trough levels in liver transplantation. | 2015 | Ann. Transplant. | pmid:25553853 |
| Mahalati K and Kahan BD | Pharmacological surrogates of allograft outcome. | 2000 | Ann. Transplant. | pmid:11217202 |
| Garlicki M et al. | Conversion from cyclosporine to tacrolimus improves renal function and lipid profile after cardiac transplantation. | 2006 | Ann. Transplant. | pmid:17025026 |
| Van Laecke S et al. | Effect of Magnesium Supplements on Insulin Secretion After Kidney Transplantation: A Randomized Controlled Trial. | 2017 | Ann. Transplant. | pmid:28848225 |
| Malinowski M et al. | The influence of commonly used immunosuppressive drugs on the small bowel functions - a comparative experimental study. | 2009 Apr-Jun | Ann. Transplant. | pmid:19487793 |
| Kishida N et al. | Increased Incidence of Thrombotic Microangiopathy After ABO-Incompatible Living Donor Liver Transplantation. | 2016 | Ann. Transplant. | pmid:27956735 |
| Illsinger S et al. | Effect of tacrolimus on energy metabolism in human umbilical endothelial cells. | 2011 Apr-Jun | Ann. Transplant. | pmid:21716189 |
| Mijal J et al. | Formation of synapses between dendritic cells and lymphocytes in skin lymph in an allogeneic reaction. | 2002 | Ann. Transplant. | pmid:12854345 |
| Thölking G et al. | Tacrolimus Concentration/Dose Ratio is Associated with Renal Function After Liver Transplantation. | 2016 | Ann. Transplant. | pmid:27003330 |
| Holechek MJ | Medication review: FK 506. | 1991 | ANNA J | pmid:1708982 |
| Schmid FX | Prolyl isomerase: enzymatic catalysis of slow protein-folding reactions. | 1993 | Annu Rev Biophys Biomol Struct | pmid:7688608 |
| Sigal NH and Dumont FJ | Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. | 1992 | Annu. Rev. Immunol. | pmid:1375473 |
| Tzakis AG et al. | Intestinal transplantation. | 1994 | Annu. Rev. Med. | pmid:7515221 |
| Hanauer SB and Dassopoulos T | Evolving treatment strategies for inflammatory bowel disease. | 2001 | Annu. Rev. Med. | pmid:11160781 |
| Pratt WB | The role of the hsp90-based chaperone system in signal transduction by nuclear receptors and receptors signaling via MAP kinase. | 1997 | Annu. Rev. Pharmacol. Toxicol. | pmid:9131255 |
| Nikitin AV | [Mechanisms of nephrotoxic action of immunodepressants, calcineurine inhibitors]. | 2014 | Antibiot. Khimioter. | pmid:25051716 |
| Romano S et al. | FK506 binding proteins as targets in anticancer therapy. | 2010 | Anticancer Agents Med Chem | pmid:21182472 |
| Epand RF and Epand RM | The new potent immunosuppressant FK-506 reverses multidrug resistance in Chinese hamster ovary cells. | 1991 | Anticancer Drug Des. | pmid:1714737 |
| Jachez B et al. | Reversion of the P-glycoprotein-mediated multidrug resistance of cancer cells by FK-506 derivatives. | 1993 | Anticancer Drugs | pmid:7683935 |
| Yamamoto M et al. | Cyclosporin A and FK506 reverse anthracycline resistance by altering the cell cycle. | 1995 | Anticancer Drugs | pmid:7579561 |
| Pourtier-Manzanedo A et al. | FK-506 (fujimycin) reverses the multidrug resistance of tumor cells in vitro. | 1991 | Anticancer Drugs | pmid:1724925 |
| Mizuno K et al. | Modulation of multidrug resistance by immunosuppressive agents: cyclosporin analogues, FK506 and mizoribine. | 1992 Jan-Feb | Anticancer Res. | pmid:1373592 |
| Pinsk V et al. | Complete Reversion of Familial Adenomatous Polyposis Phenotype Associated with Tacrolimus and Mycophenolate Mofetil Treatment Following Kidney Transplantation. | 2017 | Anticancer Res. | pmid:28551651 |
| Kalas W et al. | FK506 restores sensitivity of thymic lymphomas to calcium-mediated apoptosis and the inducible expression of Fas ligand. | 2003 Mar-Apr | Anticancer Res. | pmid:12820430 |
| Harada N et al. | Serum Asunaprevir and Daclatasvir Concentrations and Outcomes in Patients with Recurrent Hepatitis C Who Have Undergone Living Donor Liver Transplantation. | 2018 | Anticancer Res. | pmid:30194210 |
| Ling G et al. | Mycophenolate Mofetil Alone and in Combination with Tacrolimus Inhibits the Proliferation of HT-29 Human Colonic Adenocarcinoma Cell Line and Might Interfere with Colonic Tumorigenesis. | 2018 | Anticancer Res. | pmid:29848681 |
| Morisaki T et al. | A combination of cyclosporin-A (CsA) and interferon-gamma (INF-gamma) induces apoptosis in human gastric carcinoma cells. | 2000 Sep- Oct | Anticancer Res. | pmid:11131636 |
| Gornet JM et al. | Severe CPT-11-induced diarrhea in presence of FK-506 following liver transplantation for hepatocellular carcinoma. | 2001 Nov-Dec | Anticancer Res. | pmid:11911319 |
| Gauthier C et al. | Functional similarities and differences between Candida albicans Cdr1p and Cdr2p transporters. | 2003 | Antimicrob. Agents Chemother. | pmid:12709320 |
| Del Poeta M et al. | Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans. | 2000 | Antimicrob. Agents Chemother. | pmid:10681348 |
| Steinbach WJ et al. | Calcineurin inhibition or mutation enhances cell wall inhibitors against Aspergillus fumigatus. | 2007 | Antimicrob. Agents Chemother. | pmid:17502415 |
| Morikawa K et al. | Immunomodulatory effects of three macrolides, midecamycin acetate, josamycin, and clarithromycin, on human T-lymphocyte function in vitro. | 1994 | Antimicrob. Agents Chemother. | pmid:7532933 |
| Onyewu C et al. | Ergosterol biosynthesis inhibitors become fungicidal when combined with calcineurin inhibitors against Candida albicans, Candida glabrata, and Candida krusei. | 2003 | Antimicrob. Agents Chemother. | pmid:12604527 |
| Fortwendel JR et al. | Differential effects of inhibiting chitin and 1,3-{beta}-D-glucan synthesis in ras and calcineurin mutants of Aspergillus fumigatus. | 2009 | Antimicrob. Agents Chemother. | pmid:19015336 |
| Lamping E et al. | Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei. | 2009 | Antimicrob. Agents Chemother. | pmid:19015352 |
| Reedy JL et al. | Immunotherapy with tacrolimus (FK506) does not select for resistance to calcineurin inhibitors in Candida albicans isolates from liver transplant patients. | 2006 | Antimicrob. Agents Chemother. | pmid:16569889 |
| Katiyar SK et al. | Fks1 and Fks2 are functionally redundant but differentially regulated in Candida glabrata: implications for echinocandin resistance. | 2012 | Antimicrob. Agents Chemother. | pmid:23027185 |
| Vaes M et al. | Therapeutic drug monitoring of posaconazole in patients with acute myeloid leukemia or myelodysplastic syndrome. | 2012 | Antimicrob. Agents Chemother. | pmid:23027198 |
| Morikawa K et al. | Immunosuppressive activity of fosfomycin on human T-lymphocyte function in vitro. | 1993 | Antimicrob. Agents Chemother. | pmid:7509146 |
| Zhuang D et al. | Effect of calcineurin inhibitors on posaconazole blood levels as measured by the MVista microbiological assay. | 2008 | Antimicrob. Agents Chemother. | pmid:18025114 |
| Kontoyiannis DP et al. | Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: correlation with outcome in solid organ transplant recipients with cryptococcosis. | 2008 | Antimicrob. Agents Chemother. | pmid:18070977 |
| Ricardo E et al. | In vivo and in vitro acquisition of resistance to voriconazole by Candida krusei. | 2014 | Antimicrob. Agents Chemother. | pmid:24867987 |
| Coilly A et al. | Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence. | 2012 | Antimicrob. Agents Chemother. | pmid:22908172 |
| Gao L and Sun Y | In vitro interactions of antifungal agents and tacrolimus against Aspergillus biofilms. | 2015 | Antimicrob. Agents Chemother. | pmid:26303797 |
| Uppuluri P et al. | Synergistic effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms. | 2008 | Antimicrob. Agents Chemother. | pmid:18180354 |
| Odom A et al. | The immunosuppressant FK506 and its nonimmunosuppressive analog L-685,818 are toxic to Cryptococcus neoformans by inhibition of a common target protein. | 1997 | Antimicrob. Agents Chemother. | pmid:8980772 |
| Roy J et al. | The immunosuppressant rapamycin represses human immunodeficiency virus type 1 replication. | 2002 | Antimicrob. Agents Chemother. | pmid:12384349 |
| Steinbach WJ et al. | In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients. | 2004 | Antimicrob. Agents Chemother. | pmid:15561883 |
| Aoki Y and Kao PN | Erythromycin inhibits transcriptional activation of NF-kappaB, but not NFAT, through calcineurin-independent signaling in T cells. | 1999 | Antimicrob. Agents Chemother. | pmid:10543746 |
| Dannaoui E et al. | In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes. | 2009 | Antimicrob. Agents Chemother. | pmid:19451295 |
| Rivosecchi RM et al. | Effects of Isavuconazole on the Plasma Concentrations of Tacrolimus among Solid-Organ Transplant Patients. | 2017 | Antimicrob. Agents Chemother. | pmid:28674051 |
| Rosenwirth B et al. | Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a nonimmunosuppressive cyclosporine analog. | 1994 | Antimicrob. Agents Chemother. | pmid:7527198 |
| Venkataramanan R et al. | Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes. | 2002 | Antimicrob. Agents Chemother. | pmid:12183280 |